Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
Byington
R P
RP
Craven
T E
TE
Furberg
C D
CD
Pahor
M
M
D001161:Arteriosclerosis / Q000188:drug therapy; D001786:Blood Glucose / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology*; D002340:Carotid Artery Diseases / Q000188:drug therapy; D004232:Diuretics; D018149:Glucose Intolerance / Q000150:complications*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications; D017275:Isradipine / Q000009:adverse effects*; D008875:Middle Aged; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004232:Diuretics; D006442:Glycated Hemoglobin; D006852:Hydrochlorothiazide; D017275:Isradipine; D049993:Sodium Chloride Symporter Inhibitors